Personalized Medicine News and Research

RSS

Study finds increasing dosage of blood thinners can help cardiovascular disease patients with genetic defect

Cardiovascular disease patients who have a genetic defect that makes them less responsive to blood thinners may be helped with an increased dosage, according to results of an innovative pilot study led by a cardiologist at The University of Texas Health Science Center at Houston (UTHealth).

2 Nov 2010

McKesson to acquire US Oncology

McKesson Corporation, a leading healthcare services and information technology company, and US Oncology, a leading integrated oncology company, announced today that the two companies have signed a definitive agreement under which McKesson will purchase all outstanding shares of US Oncology for cash.

1 Nov 2010

University of Maryland to establish major research enterprise for autoimmune diseases

With a new $45 million private gift from the family of a grateful patient, the University of Maryland School of Medicine is planning to establish the nation's only major research enterprise devoted to the study of autoimmune and inflammatory diseases such as celiac disease, multiple sclerosis, chronic obstructive pulmonary disease, asthma and Type 1 diabetes. The gift, from Indiana couple Ken and Shelia Cafferty, is the largest private donation in the history of the University System of Maryland.

29 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

28 Oct 2010

New G-DOC repository for biological information

Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center, announces the launch of the Georgetown Database of Cancer or G-DOC. Under development for two years, G-DOC is a repository for biological information that is normally only available in scattered information libraries and tissue banks, if at all. Data sets grow as researchers deposit new information. G-DOC also contains relevant tools to analyze the data, plus new ones not seen before.

27 Oct 2010

New Australian start-up venture could lead to a revolution in personalized medicine

Pharmaceuticals that seek out cancerous cells and deliver treatments to them; imaging techniques that can help doctors detect diseases before the physical signs begin to appear; and medicines that are tailor-made for individual patients, are within the sights of an exciting new Australian start-up venture.

27 Oct 2010

AutoGenomics granted FDA 510(k) clearance for INFINITI CYP2C19 Assay

AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its INFINITI® CYP2C19 Assay. The test detects 3 genetic variants, *2, *3, *17, of the CYP450 2C19 gene and is to be used on the company's automated molecular testing platform, the INFINITI® Analyzer.

27 Oct 2010

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Antigenics, Inc. today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage® vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.

25 Oct 2010

Shrink announces agreement to produce high content screening tool for biotech R&D subsidiary

Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that it has entered into an agreement to produce a high content screening tool for its biotech R&D subsidiary, Shrink Chips LLC.

25 Oct 2010

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

21 Oct 2010

Study finds different activity patterns of genes in brain of individuals with different genetic backgrounds

Researchers at the Allen Institute for Brain Science have found that the same genes have different activity patterns in the brain in individuals with different genetic backgrounds. These findings may help to explain individual differences in the effectiveness and side-effect profiles of therapeutic drugs and thus have implications for personalized medicine. The study is available in this week's online early edition of the Proceedings of the National Academy of Sciences (www.pnas.org).

20 Oct 2010

Integration of XB-BIS and IPA software improve personalized medicine

Ingenuity Systems, the leading provider of information solutions for life science researchers, and TransMed Systems, a translational medicine software and services company, today announced an integration between IPA software and XB Bio-Integration Suite (XB-BIS).

19 Oct 2010

Possibilities of genetics research, personalized medicine, and behavioral intervention

Personalized medicine - improving the fit between patient and treatment - has become a major focus of research in fields from cancer treatment to the psychopharmacology of mental disorders. Genetic studies have suggested that an individual's genetic makeup renders him either more or less sensitive to stressful social environments - but can an individual's unique genotype also determine the effectiveness of preventative or therapeutic behavioral interventions?

18 Oct 2010

Shrink reveals image of StemDisc450 biomedical research tool

Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool.

18 Oct 2010

Experts use multi-disciplinary approach to provide innovative care for children

Liver tumors affect more than 300 children in the United States each year and management of these children requires coordinated comprehensive care from experts in many disciplines. To answer this problem, Texas Children's Hospital and Baylor College of Medicine announced today the formation of a new Liver Tumor Center that brings together renowned specialists in all aspects of liver cancer who will utilize a multi-disciplinary approach to provide the most comprehensive and innovative care for children afflicted with these diseases.

15 Oct 2010

Study: Characteristics of children with OCD could help predict personalized medicine approach

New research from the Bradley Hasbro Children's Research Center may help clinicians better predict how a child with obsessive compulsive disorder (OCD) will respond to some of the most commonly used treatment approaches. The findings, published in the October issue of the Journal of the American Academy of Child and Adolescent Psychiatry, could help guide important clinical decisions about the best intervention for children with this often debilitating anxiety disorder.

15 Oct 2010

Enzo Biochem fiscal 2010 total revenues increase 8% to $97.1 million

Enzo Biochem, Inc. today reported results for the fiscal fourth quarter, consistent with our announcement on September 20, 2010, and for the year ended July 31, 2010.

15 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

TrovaGene, Inc. a developer of transrenal molecular diagnostics to facilitate personalized medicine, received notice of U.S. Patent 7,803,929 entitled "Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine."

13 Oct 2010

Personalized Medicine News and Research

Study finds increasing dosage of blood thinners can help cardiovascular disease patients with genetic defect

McKesson to acquire US Oncology

University of Maryland to establish major research enterprise for autoimmune diseases

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

New G-DOC repository for biological information

New Australian start-up venture could lead to a revolution in personalized medicine

AutoGenomics granted FDA 510(k) clearance for INFINITI CYP2C19 Assay

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Shrink announces agreement to produce high content screening tool for biotech R&D subsidiary

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Study finds different activity patterns of genes in brain of individuals with different genetic backgrounds

Integration of XB-BIS and IPA software improve personalized medicine

Possibilities of genetics research, personalized medicine, and behavioral intervention

Shrink reveals image of StemDisc450 biomedical research tool

Experts use multi-disciplinary approach to provide innovative care for children

Study: Characteristics of children with OCD could help predict personalized medicine approach

Enzo Biochem fiscal 2010 total revenues increase 8% to $97.1 million

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News